Two weeks after MOPC315.BM injection, the myeloma load was approximately 30% reduced in anti-IL-5 treated mice, as measured by myeloma-specific anti-DNP protein in serum (Figure 4). This evidence concerns the gene IL5 and plasma cell myeloma.